jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

May. 17, 2024

Dec. 08, 2025

jRCTs062240013

High-frequency variability index-guided remifentanil versus standard care in lower extremity arthroplasty during general anesthesia: A randomized controlled trial

HFVI Study

Morimatsu Hiroshi

Okayama University Hospital

2-5-1 Shikatacho, Kitaku, Okayama

+81-86-235-7327

pb9b45wr@okayama-u.ac.jp

Matsuoka Yuto

Okayama University Hospital

2-5-1 Shikatacho, Kitaku, Okayama

+81-86-235-7330

me421078@s.okayama-u.ac.jp

Not Recruiting

May. 17, 2024

June. 25, 2024
50

Interventional

randomized controlled trial

single blind

uncontrolled control

parallel assignment

other

1.Patients scheduled to undergo unilateral knee or hip replacement under general anesthesia
2.Patients who are 18 years of age or older at the time of consent (regardless of gender)
3.Patients scheduled to enter the PACU after surgery
4.Patients who have received sufficient explanation and informed written consent of their own free will to participate in this study.

1. Patients with a history of hypersensitivity to medications to be used during anesthesia
2. Patients with a preoperative ASA-PS (American Society of Anesthesiologists Physical Status) of 3 or higher
3. Patients who have undergone surgery under general anesthesia at least 1 week before the scheduled surgery
4. Patients who have been using narcotic analgesics and antiarrhythmic drugs regularly before the surgery
5. Patients with a history of atrial fibrillation
6. Patients with a pacemaker
7. Patients who are undergoing surgery other than TKAt or THA at the same time.
8. Patients who do not understand Japanese and cannot perform NRS evaluation.
9. Other patients judged inappropriate as research subjects by the principal investigator and subinvestigators.

18age old over
No limit

Both

Osteoarthritis

1)HFVI control group
The HFVI is attached, and the HFVI value is measured. The remifentanil dosage is adjusted based on the HFVI value every 5 minutes from the start of surgery to the end of surgery as follows
HFVI 49 or lower: Remifentanil dose is increased by 0.05ug/kg/min.
HFVI 71 or higher: decrease the dose of remifentanil by 0.05ug/kg/min.
2)HFVI uncontrolled group
The HFVI value is measured with HFVI, but the HFVI value is not displayed on the monitor screen. From the start to the end of the surgery, the dose of remifentanil will be adjusted based on clinical monitoring, including vital signs as before.

Amount of remifentanil used during surgery

- NRS from the time of admission to the PACU to the day after surgery
- Use of supplemental analgesia from the time of admission to the PACU to the day after surgery
- Complications including postoperative nausea and vomiting (PONV)
- Vital signs during surgery
- HFVI values for both groups

Okayama University Certified Review Board
2-5-1 Shikata-cho, Kita-ku, Okayama City, Okayama Prefecture, Okayama

+81-86-235-6503

ouh-crrb@adm.okayama-u.ac.jp
Approval

May. 01, 2024

No

none

History of Changes

No Publication date
5 Dec. 08, 2025 (this page) Changes
4 May. 28, 2025 Detail Changes
3 Oct. 16, 2024 Detail Changes
2 July. 19, 2024 Detail Changes
1 May. 17, 2024 Detail